Safety and efficacy of statin therapy (Q58097774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

title

Safety and efficacy of statin therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

Bhavin B Adhyaru

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

Terry A Jacobson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

language of work or name

English

0 references

publication date

1 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

Nature Reviews Cardiology

1 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

757-769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Interpretation of the evidence for the efficacy and safety of statin therapy

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology T

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Rosuvastatin in older patients with systolic heart failure

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

An assessment by the Statin Muscle Safety Task Force: 2014 update.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Effect of statins on skeletal muscle function

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Risk factors for statin-associated rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin-induced myopathy: a review and update

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Cytochrome p450 and chemical toxicology

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin drug interactions and related adverse reactions

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

An assessment by the Statin Intolerance Panel: 2014 update

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

An assessment by the Statin Liver Safety Task Force: 2014 update

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statins and the liver

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statin therapy and serum transaminases among a cohort of HCV-infected veterans

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Diabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

An assessment by the Statin Cognitive Safety Task Force: 2014 update

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Clinical practice. Mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Pravastatin and cognitive function in the elderly. Results of the PROSPER study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1038/S41569-018-0098-5

7 January 2021

10.1038/S41569-018-0098-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30375494 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference